CRDL Stock Overview
A clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Cardiol Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$2.66 |
52 Week High | CA$4.26 |
52 Week Low | CA$0.91 |
Beta | 0.70 |
11 Month Change | 6.83% |
3 Month Change | 2.31% |
1 Year Change | 125.42% |
33 Year Change | -34.16% |
5 Year Change | 0.38% |
Change since IPO | -35.90% |
Recent News & Updates
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Sep 12Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?
May 01Recent updates
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Sep 12Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?
May 01Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?
Jan 06Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?
Sep 13We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
May 24We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Jan 20We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Aug 10We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn
Apr 17Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Dec 09We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
Aug 19Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Apr 18Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth
Jan 03Shareholder Returns
CRDL | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -4.3% | 0.7% | 0.6% |
1Y | 125.4% | -1.7% | 23.3% |
Return vs Industry: CRDL exceeded the Canadian Pharmaceuticals industry which returned -1.7% over the past year.
Return vs Market: CRDL exceeded the Canadian Market which returned 23.3% over the past year.
Price Volatility
CRDL volatility | |
---|---|
CRDL Average Weekly Movement | 9.3% |
Pharmaceuticals Industry Average Movement | 10.2% |
Market Average Movement | 8.2% |
10% most volatile stocks in CA Market | 17.1% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: CRDL has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CRDL's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | David Elsley | www.cardiolrx.com |
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.
Cardiol Therapeutics Inc. Fundamentals Summary
CRDL fundamental statistics | |
---|---|
Market cap | CA$185.89m |
Earnings (TTM) | -CA$29.34m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.3x
P/E RatioIs CRDL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRDL income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$29.34m |
Earnings | -CA$29.34m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.42 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CRDL perform over the long term?
See historical performance and comparison